Video

Dr. Choyke on Which Patients Benefit From Active Surveillance in Prostate Cancer

Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.

Peter Choyke, MD, FACR, chief of Molecular Imagine Program, National Cancer Institute, discusses which patients with prostate cancer benefit from active surveillance.

There is very good long-term safety data for patients who are appropriately selected for active surveillance, says Choyke.

The patients who benefit from active surveillance have very low-risk cancer with a negative MRI.

Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Ami Umesh Badami, MD
Premal Thaker, MD, MS